Nurix Therapeutics (NRIX) Operating Leases (2021 - 2025)
Historic Operating Leases for Nurix Therapeutics (NRIX) over the last 5 years, with Q4 2025 value amounting to $55.7 million.
- Nurix Therapeutics' Operating Leases rose 17468.09% to $55.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $55.7 million, marking a year-over-year increase of 17468.09%. This contributed to the annual value of $55.7 million for FY2025, which is 17468.09% up from last year.
- According to the latest figures from Q4 2025, Nurix Therapeutics' Operating Leases is $55.7 million, which was up 17468.09% from $52.7 million recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Operating Leases ranged from a high of $55.7 million in Q4 2025 and a low of $2.6 million during Q3 2023
- In the last 5 years, Nurix Therapeutics' Operating Leases had a median value of $20.0 million in 2025 and averaged $19.8 million.
- Per our database at Business Quant, Nurix Therapeutics' Operating Leases tumbled by 6588.77% in 2023 and then soared by 67933.38% in 2024.
- Quarter analysis of 5 years shows Nurix Therapeutics' Operating Leases stood at $9.2 million in 2021, then fell by 29.98% to $6.4 million in 2022, then soared by 259.42% to $23.1 million in 2023, then decreased by 12.26% to $20.3 million in 2024, then surged by 174.68% to $55.7 million in 2025.
- Its Operating Leases was $55.7 million in Q4 2025, compared to $52.7 million in Q3 2025 and $46.7 million in Q2 2025.